Search
Icatibant
go.drugbank.com/drugs/DB06196ApprovedInvestigationalIcatibant is a synthetic decapeptide with 5 nonproteinogenic amino acid antagonist targeting the B<sub>2</sub> receptors with a similar affinity to bradykinin. … It is resistant to bradykinin-cleaving enzyme degradation and has a potency of 2-3 times higher than earlier B<sub>2</sub> receptors antagonists, thus representing a new class of medication.
Rufinamide
go.drugbank.com/drugs/DB06201ApprovedRufinamide is a triazole derivative and an anticonvulsant medication to treat seizure disorders like Lennox-Gastuat syndrome, a form of childhood epilepsy.
Sugammadex
go.drugbank.com/drugs/DB06206ApprovedInvestigationalSugammadex provides a new treatment option to reverse the effects of those medications and possibly help patients recover sooner post-surgery. … Sugammadex is a selective relaxant binding agent indicated for reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide during surgery.
Categories: Compounds used in a research, industrial, or household settingTolvaptan
go.drugbank.com/drugs/DB06212ApprovedInvestigationalTolvaptan is used to treat low blood sodium levels (hyponatremia) associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH). FDA approved on May 19, 2009.
Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexIncadronic acid
go.drugbank.com/drugs/DB06255ExperimentalIncadronate, or YM-175,[A202769] is a nitrogen containing bisphosphonate.
Bimoclomol
go.drugbank.com/drugs/DB06258ExperimentalBimoclomol is an investigational drug that induces stress proteins and has cytoprotective effects.